Trial
NCT00676143
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Pfizer
Collaborators
—
Condition
Alzheimer Disease
Intervention
bapineuzumab
Why stopped
The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-10